The application of metagenomic next-generation sequencing in patients with infection or colonization caused by Lichtheimia species
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1103626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Lihua Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Mucormycosis, Mucorales, Invasive Fungal Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Science and Technology Department.
Abstract (Originalsprache)
Background
Mucormycosis is considered the fourth most common invasive fungal disease after candidiasis, aspergillosis and cryptococcosis. Lichtheimia species accounted for 5%-29% of all mucormycosis. However, available data on species-specific analysis of Lichtheimia infections are limited.
Methods
This study included nine patients hospitalized in five hospitals in two cities in south China with mucormycosis or colonization caused by Lichtheimia species, diagnosed mainly by metagenomic next-generation sequencing (mNGS). The corresponding medical records were reviewed, and the clinical data analyzed included demographic characteristics, site of infection, host factors and type of underlying disease, diagnosis, clinical course, management, and prognosis.
Results
In this study, nine patients with Lichtheimia infections or colonization had a recent history of haematological malignancy (33.3%), solid organ transplants (33.3%), pulmonary disease (22.2%), and trauma (11.1%) and were categorized as 11.1% (one case) proven, 66.7% (six cases) probable mucormycosis and 22.2% (two cases) colonization. Pulmonary mucormycosis or colonization was the predominant presentation in 77.8% of cases and mucormycosis caused by Lichtheimia resulted in death in four out of seven patients (57.1%).
Conclusion
These cases highlight the importance of early diagnosis and combined therapy for these sporadic yet life-threatening infections. Further studies on the diagnosis and control of Lichtheimia infection in China are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
- Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Transplant Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
- Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Tuberculosis, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Förderung
- Hunan Provincial Science and Technology Department
Zitieren
APA
Chen, L., Peng, W., Lan, G., Long, G., Yang, H., Xu, Y., Fu, A., Yi, H., & Wan, Q. (2023). The application of metagenomic next-generation sequencing in patients with infection or colonization caused by Lichtheimia species. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1103626
Vancouver
Chen L, Peng W, Lan G, Long G, Yang H, Xu Y, et al. The application of metagenomic next-generation sequencing in patients with infection or colonization caused by Lichtheimia species. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1103626
BibTeX
@article{Chen2023,
author = {Chen, Lihua and Peng, Weiting and Lan, Gongbin and Long, Guo and Yang, Honghui and Xu, Yajing and Fu, Ai and Yi, Huimin and Wan, Qiquan},
title = {The application of metagenomic next-generation sequencing in patients with infection or colonization caused by Lichtheimia species},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1103626}
}
EUVIMED